WO2004016248A3 - Forme galenique pour la delivrance colique de principes actifs - Google Patents

Forme galenique pour la delivrance colique de principes actifs Download PDF

Info

Publication number
WO2004016248A3
WO2004016248A3 PCT/FR2003/002474 FR0302474W WO2004016248A3 WO 2004016248 A3 WO2004016248 A3 WO 2004016248A3 FR 0302474 W FR0302474 W FR 0302474W WO 2004016248 A3 WO2004016248 A3 WO 2004016248A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeted delivery
active principles
colon targeted
galenic formulation
colon
Prior art date
Application number
PCT/FR2003/002474
Other languages
English (en)
Other versions
WO2004016248A8 (fr
WO2004016248A2 (fr
Inventor
Sandrine Bourgeois
Elias Fattal
Antoine Andremont
Patrick Couvreur
Original Assignee
Centre Nat Rech Scient
Da Volterra
Sandrine Bourgeois
Elias Fattal
Antoine Andremont
Patrick Couvreur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0210151A external-priority patent/FR2843301B1/fr
Priority to AT03758212T priority Critical patent/ATE432066T1/de
Priority to AU2003274229A priority patent/AU2003274229B2/en
Priority to JP2004528586A priority patent/JP2006500359A/ja
Priority to EP03758212A priority patent/EP1526841B1/fr
Priority to CN038213656A priority patent/CN1681480B/zh
Priority to US10/524,318 priority patent/US7485294B2/en
Priority to MXPA05001607A priority patent/MXPA05001607A/es
Application filed by Centre Nat Rech Scient, Da Volterra, Sandrine Bourgeois, Elias Fattal, Antoine Andremont, Patrick Couvreur filed Critical Centre Nat Rech Scient
Priority to DE60327772T priority patent/DE60327772D1/de
Priority to BR0313469-5A priority patent/BR0313469A/pt
Priority to CA002495291A priority patent/CA2495291A1/fr
Publication of WO2004016248A2 publication Critical patent/WO2004016248A2/fr
Publication of WO2004016248A3 publication Critical patent/WO2004016248A3/fr
Publication of WO2004016248A8 publication Critical patent/WO2004016248A8/fr
Priority to US12/345,647 priority patent/US7833765B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Formes galéniques multiparticulaires aptes à être utilisées par voie orale et destinées à la délivrance colique de principes actifs choisis dans le groupe comprenant les enzymes capables d'inactiver les macrolides et apparentés, les enzymes capables d'inactiver les quinolones et les β-lactamases.
PCT/FR2003/002474 2002-08-09 2003-08-06 Forme galenique pour la delivrance colique de principes actifs WO2004016248A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002495291A CA2495291A1 (fr) 2002-08-09 2003-08-06 Forme galenique pour la delivrance colique de principes actifs
MXPA05001607A MXPA05001607A (es) 2002-08-09 2003-08-06 Forma galenica para suministro de ingredientes activos dirigido al colon.
JP2004528586A JP2006500359A (ja) 2002-08-09 2003-08-06 有効成分の結腸標的指向送達用ガレヌス製剤形態
EP03758212A EP1526841B1 (fr) 2002-08-09 2003-08-06 Forme galenique pour la delivrance colique de principes actifs
CN038213656A CN1681480B (zh) 2002-08-09 2003-08-06 用于活性成分结肠靶向释放的盖仑制剂
US10/524,318 US7485294B2 (en) 2002-08-09 2003-08-06 Galenic pectinate formulation for colon-targeted delivery of antibiotic-inactivating enzymes and method of use thereof
DE60327772T DE60327772D1 (de) 2002-08-09 2003-08-06 Arzneimittel für die dickdarmverabreichung von wirkstoffen
AT03758212T ATE432066T1 (de) 2002-08-09 2003-08-06 Arzneimittel für die dickdarmverabreichung von wirkstoffen
AU2003274229A AU2003274229B2 (en) 2002-08-09 2003-08-06 Galenic formulation for colon targeted delivery of active ingredients
BR0313469-5A BR0313469A (pt) 2002-08-09 2003-08-06 Forma galêmica para a liberação cólica de princìpios ativos
US12/345,647 US7833765B2 (en) 2002-08-09 2008-12-29 Galenic formulation for colon-targeted delivery of active ingredients

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0210151A FR2843301B1 (fr) 2002-08-09 2002-08-09 Forme galenique pour la delivrance colique de principes actifs
FR02/10151 2002-08-09
FR02/13514 2002-10-29
FR0213514A FR2843302B1 (fr) 2002-08-09 2002-10-29 Forme galenique pour la delivrance colique de principes actifs

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/524,318 A-371-Of-International US7485294B2 (en) 2002-08-09 2003-08-06 Galenic pectinate formulation for colon-targeted delivery of antibiotic-inactivating enzymes and method of use thereof
US12/345,647 Continuation US7833765B2 (en) 2002-08-09 2008-12-29 Galenic formulation for colon-targeted delivery of active ingredients

Publications (3)

Publication Number Publication Date
WO2004016248A2 WO2004016248A2 (fr) 2004-02-26
WO2004016248A3 true WO2004016248A3 (fr) 2004-04-08
WO2004016248A8 WO2004016248A8 (fr) 2004-05-21

Family

ID=30772009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002474 WO2004016248A2 (fr) 2002-08-09 2003-08-06 Forme galenique pour la delivrance colique de principes actifs

Country Status (14)

Country Link
US (2) US7485294B2 (fr)
EP (2) EP1992336A3 (fr)
JP (1) JP2006500359A (fr)
KR (1) KR101080577B1 (fr)
CN (1) CN1681480B (fr)
AT (1) ATE432066T1 (fr)
AU (1) AU2003274229B2 (fr)
BR (1) BR0313469A (fr)
CA (1) CA2495291A1 (fr)
DE (1) DE60327772D1 (fr)
ES (1) ES2327630T3 (fr)
FR (1) FR2843302B1 (fr)
MX (1) MXPA05001607A (fr)
WO (1) WO2004016248A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4694145B2 (ja) * 2004-05-17 2011-06-08 株式会社 メドレックス 経口腸溶性製剤
BRPI0606943A2 (pt) * 2005-02-09 2009-07-28 Da Volterra fornecimento no cólon de agentes ativos
ES2429095T3 (es) * 2005-05-18 2013-11-13 Da Volterra Aporte colónico de adsorbentes
WO2006129386A1 (fr) * 2005-06-03 2006-12-07 Medrx Co., Ltd. Composition médicinale entérique pour utilisation orale
US8048413B2 (en) * 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
FI119678B (fi) * 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
GB0714226D0 (en) * 2007-07-20 2007-08-29 Therapeutics Ltd E anti-bacterial combination therapy
US20100239682A1 (en) * 2007-09-17 2010-09-23 Antoine Andremont Colonic delivery of antimicrobial agents
GB0719771D0 (en) * 2007-10-10 2007-11-21 Therapeutics Ltd E Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma
GB0813211D0 (en) 2008-07-18 2008-08-27 E Therapeutics Plc Antibacterial combination therapy for the treatment of gram positive bacterial infections
FR2950252B1 (fr) * 2009-09-23 2012-01-20 Centre Nat Rech Scient Forme galenique capable d'adsorber de maniere specifique les molecules indesirables
HUE029299T2 (en) 2010-02-23 2017-02-28 Da Volterra Preparations for delivery of adsorbents to the intestine by mouth
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
BR112016023360B1 (pt) 2014-04-17 2023-03-07 Synthetic Biologics, Inc Beta-lactamase e seu uso
JP6803328B2 (ja) 2014-08-28 2021-01-06 シンセティック バイオロジクス，インコーポレイテッド 大腸菌ベースでのベータラクタマーゼ生産
MX2017004473A (es) 2014-10-08 2017-10-12 Synthetic Biologics Inc Formulaciones de betalactamasa y usos de las mismas.
FR3027307B1 (fr) * 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
EP3236993B1 (fr) 2014-12-23 2023-09-13 Theriva Biologics, Inc. Méthodes et compositions pour inhiber ou prévenir les effets néfastes des antibiotiques oraux
US20160250304A1 (en) 2015-02-23 2016-09-01 Synthetic Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
KR20170122776A (ko) 2015-03-06 2017-11-06 신세틱 바이오로직스, 인코퍼레이티드 마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
US10988749B2 (en) 2016-02-23 2021-04-27 Da Volterra Beta-lactamase variants
BR112018016889A2 (pt) 2016-02-23 2019-02-12 Da Volterra variantes de beta-lactamase
CN111511350B (zh) 2017-07-07 2023-10-13 埃皮辛特瑞柯斯公司 用于治疗剂的肠胃外施用的组合物
MX2020004319A (es) 2017-10-25 2020-10-12 Da Volterra Variantes de beta-lactamasas.

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
EP0213303A2 (fr) * 1985-07-12 1987-03-11 Bo Magnus Ekman Procédé pour préparer de petites particules sphériques de polymères
EP0273823A1 (fr) * 1986-12-18 1988-07-06 Systems Bio-Industries Microcapsules à base de gélatine et de polysaccharide et leur procédé d'obtention
EP0338499A2 (fr) * 1988-04-18 1989-10-25 Nabisco Brands, Inc. Acides gras hautement insaturés et stabilisés et leurs dérivés
EP0454044A2 (fr) * 1990-04-25 1991-10-30 Hoechst Aktiengesellschaft Produit pharmacologique contenant des composés de polyélectrolytes sous forme de microparticules et au moins un agent actif
JPH0413741A (ja) * 1990-05-02 1992-01-17 Chisso Corp ペクチン・ポリリシン高分子電解質複合体
WO1992000732A1 (fr) * 1990-07-04 1992-01-23 Kabi Pharmacia Ab Composition therapeutique et procede utilise pour sa preparation
EP0480729A1 (fr) * 1990-10-11 1992-04-15 Korea Research Institute Of Chemical Technology Microencapsulation pour système de débit contrôlé de médicaments oraux
WO1993013795A1 (fr) * 1992-01-17 1993-07-22 Pekka Untamo Heino Application medicale, procede medical et preparation pharmaceutique
WO1993013757A1 (fr) * 1992-01-17 1993-07-22 Alfatec-Pharma Gmbh Corps solides renfermant une matiere active, a structure composee de macromolecules hydrophiles, et leur procede de fabrication
WO1995005939A1 (fr) * 1993-08-25 1995-03-02 Fmc Corporation Microparticules hydrocolloidales non agglutinantes, leurs intermediaires et procedes de production et de preparation
WO1997027843A2 (fr) * 1996-01-30 1997-08-07 Advanced Polymer Systems, Inc. Apport cible de medicaments sur la partie inferieure du tractus gastro-intestinal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
JPH0818971B2 (ja) 1989-02-16 1996-02-28 ブリティッシュ・テクノロジー・グループ・リミテッド 投与製剤
JPH0413724A (ja) 1990-05-02 1992-01-17 Chisso Corp 可溶性ポリイミド、その製造法及び液晶配向膜用塗布液
DE69726446T2 (de) * 1996-10-09 2004-08-26 Givaudan S.A. Verfahren zur herstellung eines perlförmigen nahrungsmittelzusatzes
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
IL130303A0 (en) * 1999-06-03 2000-06-01 M G Novobiotech Ltd A bacterial strain processed plant extracts and probiotic compositions for human and veterinary use
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
IL152127A0 (en) * 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
EP0213303A2 (fr) * 1985-07-12 1987-03-11 Bo Magnus Ekman Procédé pour préparer de petites particules sphériques de polymères
EP0273823A1 (fr) * 1986-12-18 1988-07-06 Systems Bio-Industries Microcapsules à base de gélatine et de polysaccharide et leur procédé d'obtention
EP0338499A2 (fr) * 1988-04-18 1989-10-25 Nabisco Brands, Inc. Acides gras hautement insaturés et stabilisés et leurs dérivés
EP0454044A2 (fr) * 1990-04-25 1991-10-30 Hoechst Aktiengesellschaft Produit pharmacologique contenant des composés de polyélectrolytes sous forme de microparticules et au moins un agent actif
JPH0413741A (ja) * 1990-05-02 1992-01-17 Chisso Corp ペクチン・ポリリシン高分子電解質複合体
WO1992000732A1 (fr) * 1990-07-04 1992-01-23 Kabi Pharmacia Ab Composition therapeutique et procede utilise pour sa preparation
EP0480729A1 (fr) * 1990-10-11 1992-04-15 Korea Research Institute Of Chemical Technology Microencapsulation pour système de débit contrôlé de médicaments oraux
WO1993013795A1 (fr) * 1992-01-17 1993-07-22 Pekka Untamo Heino Application medicale, procede medical et preparation pharmaceutique
WO1993013757A1 (fr) * 1992-01-17 1993-07-22 Alfatec-Pharma Gmbh Corps solides renfermant une matiere active, a structure composee de macromolecules hydrophiles, et leur procede de fabrication
WO1995005939A1 (fr) * 1993-08-25 1995-03-02 Fmc Corporation Microparticules hydrocolloidales non agglutinantes, leurs intermediaires et procedes de production et de preparation
WO1997027843A2 (fr) * 1996-01-30 1997-08-07 Advanced Polymer Systems, Inc. Apport cible de medicaments sur la partie inferieure du tractus gastro-intestinal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199209, Derwent World Patents Index; Class A23, AN 1992-069512, XP002237389 *

Also Published As

Publication number Publication date
US20090162339A1 (en) 2009-06-25
DE60327772D1 (de) 2009-07-09
CN1681480A (zh) 2005-10-12
CA2495291A1 (fr) 2004-02-26
ATE432066T1 (de) 2009-06-15
FR2843302B1 (fr) 2004-10-22
US7485294B2 (en) 2009-02-03
AU2003274229A1 (en) 2004-03-03
CN1681480B (zh) 2010-04-14
US20050249716A1 (en) 2005-11-10
KR101080577B1 (ko) 2011-11-04
EP1992336A3 (fr) 2009-05-13
WO2004016248A8 (fr) 2004-05-21
BR0313469A (pt) 2005-07-12
JP2006500359A (ja) 2006-01-05
AU2003274229B2 (en) 2009-05-21
EP1992336A2 (fr) 2008-11-19
WO2004016248A2 (fr) 2004-02-26
US7833765B2 (en) 2010-11-16
KR20050083628A (ko) 2005-08-26
EP1526841B1 (fr) 2009-05-27
ES2327630T3 (es) 2009-11-02
FR2843302A1 (fr) 2004-02-13
EP1526841A2 (fr) 2005-05-04
MXPA05001607A (es) 2005-09-20

Similar Documents

Publication Publication Date Title
WO2004016248A8 (fr) Forme galenique pour la delivrance colique de principes actifs
WO2006035417A3 (fr) Preparations de dihydropyrimidine
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
WO2002070438A3 (fr) Compositions permettant l'administration de biophosphonates
HK1034183A1 (en) Galenic formulations of meloxicam for oral administration.
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
WO2003082247A3 (fr) Microparticules medicamenteuses
AU2003296897A1 (en) Pharmaceutical formulations of camptothecine derivatives
WO2001078680A3 (fr) Compositions pharmaceutiques
WO2003026743A3 (fr) Formulations d'opioides presentant un potentiel reduit pour des utilisations abusives
IL161857A0 (en) Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
WO2005065660A3 (fr) Formulations de ziprasidone
WO2003045306A3 (fr) Composes phenoxy amine et compositions pour administrer des principes actifs
WO2004100926A3 (fr) Materiaux pouvant etre traites a l'humidite pour la delivrance d'agents, procedes, et dispositifs medicaux
WO2002019969A3 (fr) Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs
WO2003028696A3 (fr) Compositions pour l'administration de combinaisons medicinales
WO2004032866A3 (fr) Preparations therapeutiques
WO2002015959A3 (fr) Composes et compositions permettant de distribuer des agents actifs
WO2005034999A3 (fr) Composition pharmaceutique
AU2003246567A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
WO2004041158A3 (fr) Compositions de rifalazil et regimes therapeutiques
WO2005039481A3 (fr) Systeme d'administration de medicament par voie orale
WO2003041656A3 (fr) Systeme de liberation prolongee de medicaments solubles
WO2005009407A3 (fr) Formulations pharmaceutiques d'olanzapine administrees par voie orale
ZA200303113B (en) Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 09/2004 UNDER (72, 75) THE NATIONALITY AND RESIDENCE OF "COUVREUR, PATRICK" SHOULD READ "¢FR/FR!"

ENP Entry into the national phase

Ref document number: 2495291

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003274229

Country of ref document: AU

Ref document number: 10524318

Country of ref document: US

Ref document number: 2004528586

Country of ref document: JP

Ref document number: PA/A/2005/001607

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057002387

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003758212

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038213656

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003758212

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057002387

Country of ref document: KR